nnc0114-0006
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01565408)
Timeline
Indications
Mechanism of action
- Interleukin-21BINDING AGENT
Interleukin-21 binding agent
- Interleukin-21INHIBITOR
IL21 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSL1SQ55DADE ↗
- ChEMBLCHEMBL4297797 ↗
Also known as
- nnc0114-0006
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02443155 | Phase 2 | Nov 10, 2015 | Novo Nordisk |
| NCT01751152 | Phase 2 | Feb 1, 2013 | Novo Nordisk |
| NCT01647451 | Phase 2 | Sep 1, 2012 | Novo Nordisk |
| NCT01689025 | Phase 1 | Sep 1, 2012 | Novo Nordisk |
| NCT01565408 | Phase 1 | Mar 1, 2012 | Novo Nordisk |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 5 | 5 | 2 | 2012 |
1 organizations
Page 1 / 1